<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146289</url>
  </required_header>
  <id_info>
    <org_study_id>502.469</org_study_id>
    <nct_id>NCT00146289</nct_id>
  </id_info>
  <brief_title>The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects</brief_title>
  <official_title>A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether MICARDIS® improves insulin&#xD;
      sensitivity in overweight or obese, non-diabetic, normotensive subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the change from baseline to the end of study (16 weeks) in the insulin sensitivity index as estimated by the composite index (R04-1184) calculated from a 3-hour oral glucose tolerance test (OGTT).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>From baseline: Glucose disposal rates; Insulin sensitivity (IS) index as Rd/I (clamp); IS index (OGTT- min model); Insulin secretion capacity; fasting insulin &amp; gluc.; AUC gluc &amp; insulin; ratio of AUC glucose ÷ by AUC insulin; lipids &amp; inflam. markers.</measure>
  </secondary_outcome>
  <enrollment>138</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MICARDIS® (telmisartan)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to provide written informed consent in accordance with Good Clinical Practice&#xD;
             (GCP) and local legislation.&#xD;
&#xD;
          2. Subjects 18-65 years old.&#xD;
&#xD;
          3. Body Mass Index (BMI) &gt;= 28.&#xD;
&#xD;
          4. Sedentary life style defined as: Does not engage in vigorous activity for more than 30&#xD;
             minutes per day, more than two times per week.&#xD;
&#xD;
          5. Waist circumference &gt;= 40 inches (102 cm) in men and &gt;= 35 inches (89 cm) women.&#xD;
&#xD;
          6. HbA1C assessed &lt;= 6.5%.&#xD;
&#xD;
          7. Triglycerides &gt;= 150, and &lt;= 500 mg/dL.&#xD;
&#xD;
          8. Fasting Glucose &lt;= 126 mg/dL.&#xD;
&#xD;
          9. Blood pressure &gt;= 110/64 and &lt;= 140/90 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently taking any antihypertensive medications (e.g., thiazide or loop diuretics),&#xD;
             diabetic medications, medications known to alter insulin sensitivity (e.g., statins),&#xD;
             steroids, glucocorticoids, niacin, nicotinic acid, and anti-psychotic/depressant drugs&#xD;
             (e.g., prozocin). Including over the counter (OTC) and herbal products, which are&#xD;
             known to affect metabolic function.&#xD;
&#xD;
          2. Diagnosis of any of the following chronic diseases: hypertension, diabetes mellitus,&#xD;
             renal insufficiency, congestive heart failure, hepatic insufficiency, biliary&#xD;
             obstructive disorders, autoimmune disease, HIV, coronary artery disease, mental&#xD;
             illness, and severe anemia.&#xD;
&#xD;
          3. Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other&#xD;
             clinically relevant cardiac arrhythmias as determined by the investigator.&#xD;
&#xD;
          4. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant&#xD;
             stenosis of the aortic or mitral valve.&#xD;
&#xD;
          5. Unstable angina or myocardial infarction or cardiac surgery within the past 3 months.&#xD;
&#xD;
          6. PCI (percutaneous coronary intervention) within the past 3 months.&#xD;
&#xD;
          7. Stroke within the past 6 months.&#xD;
&#xD;
          8. Bilateral renal artery stenosis or obstructive disorders, renal artery stenosis in a&#xD;
             solitary kidney, post-renal transplant patients or patients with only one kidney.&#xD;
&#xD;
          9. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:&#xD;
&#xD;
               -  SGPT (ALT) or SGOT (AST) &gt; 2.5 times the upper limit of normal range, or&#xD;
&#xD;
               -  Serum creatinine &gt; 2.3 mg/dL (or &gt; 203 mol/L)&#xD;
&#xD;
         10. Pre-menopausal women (last menstruation &lt;=1 year prior to signing informed consent)&#xD;
             who:&#xD;
&#xD;
               -  Have a positive urine pregnancy test (UPT) prior to randomisation (Visit 2 or&#xD;
                  Visit 2.1 for subject participating in the clamp procedure)&#xD;
&#xD;
               -  Are not surgically sterile, or&#xD;
&#xD;
               -  Are nursing, or pregnant, or&#xD;
&#xD;
               -  Are of child-bearing potential and are NOT practicing acceptable methods of birth&#xD;
                  control, or do NOT plan to continue practicing an acceptable method throughout&#xD;
                  the study and do not agree to periodic pregnancy testing during participation in&#xD;
                  the study. Acceptable methods of birth control are limited to: Intra-Uterine&#xD;
                  Device (IUD), oral, implantable or injectable contraceptives and estrogen patch.&#xD;
                  No exceptions will be made.&#xD;
&#xD;
         11. Hematocrit &lt; 35%.&#xD;
&#xD;
         12. Primary aldosteronism.&#xD;
&#xD;
         13. Hereditary fructose intolerance.&#xD;
&#xD;
         14. History of drug or alcohol dependency within the previous 6 months.&#xD;
&#xD;
         15. Currently participating in a weight loss program.&#xD;
&#xD;
         16. Any investigational drug therapy within one month of randomisation or during the&#xD;
             study.&#xD;
&#xD;
         17. Known hypersensitivity to any component of the study drug (telmisartan or placebo).&#xD;
&#xD;
         18. Any circumstances the Investigator feels participation in the study would hinder&#xD;
             subject safety or completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA School of Medicine- Divison of Endocrinology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of CA at SanDiego- Department of Endocrinology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harker Heights</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba, Diabetes Research Group</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Care London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - Riverside Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Århus Sygehus</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Künzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterschneidheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Monteluce</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale Università di Pisa</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.469_U06-3205.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.469_literature.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

